Investors News Releases Sign up for email alerts to receive company and investor updates News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Jan 30 2024 Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer Jan 08 2024 Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement Jan 02 2024 Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024 Dec 22 2023 Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules Dec 18 2023 Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions Dec 12 2023 Cyclacel Pharmaceuticals Announces Reverse Stock Split Nov 30 2023 Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC Nov 28 2023 Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q Nov 13 2023 Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update Nov 07 2023 Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results Aug 09 2023 Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update Aug 03 2023 Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results May 11 2023 Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update May 04 2023 Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results May 03 2023 Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit Mar 07 2023 Cyclacel Pharmaceuticals to Participate in March Investor Conferences Mar 06 2023 Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update Feb 27 2023 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results Jan 30 2023 Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference Jan 05 2023 Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023 Dec 15 2022 Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023 Nov 09 2022 Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update Nov 03 2022 Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results Oct 26 2022 Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022 Oct 24 2022 Cyclacel Hosting Research & Development Day Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Jan 30 2024 Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer Jan 08 2024 Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement Jan 02 2024 Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024 Dec 22 2023 Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules Dec 18 2023 Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions Dec 12 2023 Cyclacel Pharmaceuticals Announces Reverse Stock Split Nov 30 2023 Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC Nov 28 2023 Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q Nov 13 2023 Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update Nov 07 2023 Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results Aug 09 2023 Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update Aug 03 2023 Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results May 11 2023 Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update May 04 2023 Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results May 03 2023 Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit Mar 07 2023 Cyclacel Pharmaceuticals to Participate in March Investor Conferences Mar 06 2023 Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update Feb 27 2023 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results Jan 30 2023 Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference Jan 05 2023 Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023 Dec 15 2022 Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023 Nov 09 2022 Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update Nov 03 2022 Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results Oct 26 2022 Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022 Oct 24 2022 Cyclacel Hosting Research & Development Day Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
Jan 30 2024 Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
Dec 22 2023 Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
Dec 18 2023 Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
Nov 30 2023 Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
Nov 28 2023 Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
Nov 13 2023 Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
Aug 09 2023 Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
May 11 2023 Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
Mar 06 2023 Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update
Jan 05 2023 Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023
Dec 15 2022 Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023
Nov 09 2022 Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Oct 26 2022 Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022
